1. In Vivo

Rethinking Commercialization Models In The Age Of Pricing And Access Complexity

 
• By David Wild

In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.

With Growing Market Complexity, Multidisciplinary Commercial Teams Will Be Key To Future Success • Source: Shutterstock

The commercial challenges of the next few years will be different than those of the past. No longer simply a race to capture market share, biopharma companies now have to contend with the weight of pricing pressures and market access legislation. The Inflation Reduction Act in the US, the European Union’s proposed EU-wide compulsory licensing plan, and other anticipated market and policy changes are requiring new investments in commercial models. ([A#PS148689)]

In a recent report, The Next Era Of Commercialization, Accenture looked back at commercial investments between 2018 and 2022 among...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By Jo Shorthouse

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.